CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
bortezomib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00458822
NCT00458822Phase 2Completed
CompareCT.gov

Risk-Adapted Intravenous Melphalan With Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Patients With Systemic Light-Chain (AL) Amyloidosis

Memorial Sloan Kettering Cancer Center·interventional·Posted Apr 11, 2007·Updated Aug 10, 2016

In Brief

A Phase 2 clinical trial evaluating bortezomib and dexamethasone for Multiple Myeloma and Plasma Cell Neoplasm. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study in patients needing treatment for AL amyloidosis is to see how well treatment with IV melphalan works and then, if some clonal plasma cells are still present about 2 to 3 months after melphalan treatment, to see how well treatment with bortezomib and dexamethasone works to reduce the rest of the clonal plasma cell disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma and Plasma Cell Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 11, 2007
Enrollment StartFeb 1, 2007
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 19.2 years ago

Interventions

bortezomibdrug

Given IV

dexamethasonedrug

Given orally